Additionally, as a predictor of non-reactivity, elevations in SDF-1 alpha levels are found in patients with recurrent glioblastoma showing tumor progression, and elevations in TIE2 (TEK receptor tyrosine kinase 2) are also observed in association with tumor progression [45]. This evidence concerns the gene TEK and glioblastoma.